Benefit vs cost: ASCO unveils cancer drug 'value' tool
This article was originally published in Scrip
Executive Summary
The American Society of Clinical Oncology (ASCO) asked the question "What is a cancer drug's true value?" and in four very specific treatment situations the organization's Value in Cancer Care Task Force supplied an answer: It depends.
You may also be interested in...
Oncology Is Booming But Cost Outlook Is Grim, IMS Says
The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new IMS report.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.